Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2021-03-29 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
北京神州细胞生物技术集团股份公司2021年度向特定对象发行A股股票募集说明书（申报稿）
Capital/Financing Update Classification · 100% confidence The document is titled as a "募集说明书" which translates to a "Prospectus" or "Offering Circular" for a specific issuance of A shares by Beijing Sinocelltech Group Limited in 2021. It contains detailed information about the issuer, shareholding structure, use of proceeds, risk factors, and legal statements related to the issuance. This type of document is a capital raising disclosure related to a specific share issuance to particular investors. It is not an annual report, earnings release, or management discussion, but rather a detailed capital/financing update describing the terms and purpose of the share issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is the full prospectus, not just an announcement or summary.
2021-03-29 Chinese
神州细胞关于向特定对象发行A股股票申请获得上海证券交易所受理的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (565 characters) regarding the acceptance by the Shanghai Stock Exchange of the company's application for a specific issuance of A shares. It mentions the regulatory review process and the need for approval by the China Securities Regulatory Commission. There is no detailed financial data or report content, only a notification of the acceptance of the application and the ongoing process. This fits the category of a Capital/Financing Update (CAP) as it relates to fundraising activities and capital structure changes. The document is not a full report, nor is it a mere publication announcement or regulatory filing. Therefore, the classification is CAP with high confidence.
2021-03-29 Chinese
神州细胞2020年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2020年度业绩快报公告" which translates to "2020 Annual Performance Express Report Announcement." It contains preliminary financial data for the year 2020, including revenue, profit, and asset figures, but explicitly states that the data is unaudited and preliminary. It also mentions that the final audited data will be in the company's 2020 Annual Report. The document is relatively short (1769 characters) and serves as a quick financial update rather than a full comprehensive report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. It is not the full Annual Report (10-K), nor is it an announcement of the report publication (RPA) because it contains substantive preliminary financial data. Therefore, the correct classification is Earnings Release (ER). FY 2020
2021-02-23 Chinese
神州细胞2021年第一次临时股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening and proceedings of the 2021 first extraordinary general meeting (临时股东大会) of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It details the legal compliance of the meeting's convening, attendance, voting procedures, and results. The document includes detailed voting results on various resolutions, many related to a specific share issuance to particular investors. The document is not a financial report, earnings release, or management discussion but a legal opinion on the shareholder meeting and its resolutions. This type of document corresponds to a Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting outcomes of a shareholder meeting. The document length is substantial and contains detailed voting data, not merely an announcement of a report publication or a brief notice. Therefore, the correct classification is DVA with high confidence.
2021-02-09 Chinese
神州细胞2021年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2021 first extraordinary general meeting of shareholders of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It includes voting results for multiple proposals related to a specific share issuance plan, changes in company capital, and related matters. The document contains detailed voting statistics, meeting attendance, and legal witness statements. It is not a full financial report, audit report, or earnings release. It is not a proxy solicitation or investor presentation. The content is focused on the official results of shareholder votes at a general meeting. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (8004 characters) and detailed voting data support this classification with high confidence.
2021-02-09 Chinese
神州细胞关于变更保荐机构后重新签订募集资金专户存储三方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding the change of the sponsoring institution and the re-signing of a tripartite supervision agreement for the storage of raised funds. It details the background of the fundraising, the signing of the new agreement, and the management of the raised funds accounts. The document references regulatory approvals, fundraising amounts, and supervisory responsibilities but does not contain financial statements or detailed financial performance data. It is a regulatory announcement about fundraising management and compliance rather than a financial report or audit. The document length is 3323 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2021-02-08 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.